Table 3 Relationships between the protein expressions and clinicopathological factors in early-stage diseases
Stages I–II (n=102) | P53 | Phospho-p53 | Wip1 | Nuclear phospho-p38 | Cytoplasmic phospho-p38 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive | Negative | High | Low | High | Low | High | Low | High | Low | ||||||
n=21 | n=81 | p-value | n=57 | n=45 | p-value | n=18 | n=84 | p-value | n=50 | n=52 | p-value | n=9 | n=93 | p-value | |
Age ≥60 | 4 (19%) | 23 (28%) | 0.58 | 13 (23%) | 14 (31%) | 0.37 | 7 (39%) | 20 (24%) | 0.24 | 13 (26%) | 14 (27%) | 1 | 3 (33%) | 24 (26%) | 0.70 |
FIGO stage I | 17 (81%) | 65 (80%) | 1 | 48 (84%) | 34 (76%) | 0.32 | 14 (78%) | 68 (81%) | 0.75 | 44 (88%) | 38 (73%) | 0.081 | 9 (100%) | 73 (78%) | 0.20 |
Pure histology | 21 (100%) | 78 (96%) | 1 | 55 (96%) | 44 (98%) | 1 | 17 (94%) | 82 (98%) | 0.45 | 49 (98%) | 50 (96%) | 1 | 8 (89%) | 91 (98%) | 0.24 |
Positive peritoneal cytology | 7 (33%) | 24 (30%) | 0.79 | 23 (40%) | 8 (18%) | 0.017 | 1 (6%) | 30 (36%) | 0.011 | 18 (36%) | 13 (25%) | 0.28 | 4 (44%) | 27 (29%) | 0.45 |
Endometriosis present | 13 (62%) | 45 (56%) | 0.63 | 37 (65%) | 21 (47%) | 0.073 | 13 (72%) | 45 (54%) | 0.19 | 29 (58%) | 29 (56%) | 0.84 | 5 (56%) | 53 (57%) | 1 |
Residual tumor present | 0 (0%) | 2 (2%) | 1 | 1 (2%) | 1 (2%) | 1 | 0 (0%) | 2 (2%) | 1 | 1 (2%) | 1 (2%) | 1 | 0 (0%) | 2 (2%) | 1 |
Lymphadenectmy undone | 2 (10%) | 13 (16%) | 0.73 | 6 (11%) | 9 (20%) | 0.26 | 4 (22%) | 11 (13%) | 0.30 | 5 (10%) | 10 (19%) | 0.26 | 1 (11%) | 14 (15%) | 1 |
Adjuvant chemotherapy performed | 19 (90%) | 76 (94%) | 0.63 | 53 (93%) | 42 (93%) | 1 | 17 (94%) | 78 (93%) | 1 | 47 (94%) | 48 (92%) | 1 | 8 (89%) | 87 (94%) | 0.49 |